Amifampridine and Lazanda
Determining the interaction of Amifampridine and Lazanda and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Amifampridine may cause seizures in some patients, and combining it with other medications that can also cause seizures such as fentaNYL may increase that risk. You may be more susceptible if you are elderly, undergoing alcohol or drug withdrawal, have a history of seizures, or have a condition affecting the central nervous system such as a brain tumor or head trauma. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold. Seizures have occurred in patients without a history of seizures taking amifampridine at recommended dosages and at various times after initiation of treatment. Reported incidence is approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold.
MANAGEMENT: Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin). Consider discontinuation or dose reduction of amifampridine in patients who experience a seizure during treatment. Use of amifampridine is contraindicated in patients with a history of seizures.
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- "Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc., Coral Gables, FL.
Generic Name: amifampridine
Brand name: Firdapse, Ruzurgi
Synonyms: n.a.
Generic Name: fentanyl
Brand name: Lazanda, Abstral, Fentora, Subsys, Actiq, Duragesic, Ionsys, Onsolis, Sublimaze
Synonyms: Lazanda Nasal Spray
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Amifampridine-Lazanda Nasal Spray
- Amifampridine-Leader Acid Control
- Amifampridine-Leader Acid Reducer Maximum Strength
- Amifampridine-Leader All Day Allergy
- Amifampridine-Leader Allergy D 12
- Amifampridine-Leader Allergy Relief
- Lazanda-Amifampridine Phosphate
- Lazanda-Amifampridine Tablets (Firdapse)
- Lazanda-Amifampridine Tablets (Ruzurgi)
- Lazanda-Amifostine
- Lazanda-Amifostine Intravenous
- Lazanda-Amikacin